Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy
NCT01973725
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG:
Icotinib Hydrochloride
Sponsor
Yuhong Li